3XV Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 38.35 |
52 Week High | SEK 46.80 |
52 Week Low | SEK 30.25 |
Beta | 2.13 |
11 Month Change | -10.29% |
3 Month Change | -17.26% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 25.53% |
Recent News & Updates
Recent updates
Shareholder Returns
3XV | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -3.8% | -1.0% | -0.02% |
1Y | n/a | -7.3% | 8.2% |
Return vs Industry: Insufficient data to determine how 3XV performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 3XV performed against the German Market.
Price Volatility
3XV volatility | |
---|---|
3XV Average Weekly Movement | 4.7% |
Medical Equipment Industry Average Movement | 5.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3XV has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 3XV's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 161 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.
Xvivo Perfusion AB (publ) Fundamentals Summary
3XV fundamental statistics | |
---|---|
Market cap | €1.24b |
Earnings (TTM) | €17.76m |
Revenue (TTM) | €65.27m |
69.6x
P/E Ratio18.9x
P/S RatioIs 3XV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3XV income statement (TTM) | |
---|---|
Revenue | SEK 750.59m |
Cost of Revenue | SEK 192.08m |
Gross Profit | SEK 558.52m |
Other Expenses | SEK 354.25m |
Earnings | SEK 204.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
Earnings per share (EPS) | 6.48 |
Gross Margin | 74.41% |
Net Profit Margin | 27.21% |
Debt/Equity Ratio | 0% |
How did 3XV perform over the long term?
See historical performance and comparison